Why Celcuity Stock Popped Today

By Eric Volkman – Mar 26, 2026 at 8:05PM ESTKey PointsIt very much surprised on the upside on the bottom-line result.It also has a much longer cash runway than it did at the end of 2024.On Thursday, Celcuity (CELC +3.58%) issued its final business update and set of financial results for 2025. Investors were particularly encouraged by the clinical-stage biotech's far narrower-than-expected net loss for the year's final quarter, and expressed their appreciation by bidding the stock up by more than 4% on the day. Upside surprise Celcuity, which is currently in a pure research and development phase, did not report any revenue for either the fourth quarter or the full-year 2025. During the quarter, its operating expenses increased to over $49 million from over $36 million in the same period of 2024. Image source: Getty Images. As for the bottom line, net loss not under generally accepted accounting principles (GAAP) deepened, but not alarmingly so, to $38.4 million ($0.73 per share) from the year-ago deficit of $32.3 million. Analysts tracking the stock were likely not expecting Celcuity to be so disciplined. They were modeling a much deeper net loss of $1.05 per share. One of the more encouraging aspects of that earnings release was the company's anticipation of topline results from a phase 3 clinical trial of gedatolisib in the treatment of advanced breast cancer. These should be available in the second quarter. ExpandNASDAQ: CELCCelcuityToday's Change(3.58%) $3.95Current Price$114.17Key Data PointsMarket Cap$5.1BDay's Range$108.75 - $118.7352wk Range$7.58 - $120.31Volume54KAvg Vol709K Room to run Even if Celcuity doesn't hit the target for the promising gedatolisib, it's heartening that it's built a solid cash foundation. Its cash and cash equivalents totaled nearly $166 million at the end of the quarter, up from $22.5 million at end-2024. That should give it plenty of runway, which is always a consideration for pre-revenue biotechs. With that tailwind at its back and the gedatolisib late-stage trial results (hopefully) coming soon, this is a company packed with promise. Like many market players who bought into it just after that earnings release, I'd be bullish on its future too.Read NextMar 13, 2026 •By Jonathan PoncianoInside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer DrugMar 10, 2026 •By Jake LerchApis Capital Trims Holdings of Celcuity Stock, According to Recent SEC FilingMar 6, 2026 •By Jake LerchInvestment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC FilingMar 26, 2026 •By Josh Kohn-LindquistStock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data DisappointsMar 26, 2026 •By Prosper Junior Bakiny2 Healthcare Stocks That Could Soar Over the Next 5 YearsMar 26, 2026 •By Daniel SparksNvidia Stock Has Gone Nowhere for 6 Months.

What Will It Take for Shares to Go Higher?About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedCelcuityNASDAQ: CELC$114.17(+3.58%)+$3.95*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.